Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (272)	12/27/2002 11:28:23 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 469

from 6-K, 1 October 2002....... 5. Other investments BioInvent International AB GBP'000 ______NeoGenesis Pharmaceuticals Inc GBP'000 ______ Total GBP'000 ______ Cost: At 1 January 2002 -4,2514,251 Additions 3,528-3,528 At 30 June 20023,5284,2517,779 Provisions: At 1 January 2002 and 30 June 2002--- Net book value: At 30 June 20023,5284,2517,779 Net book value: At 31 December 2001-4,2514,251 On 16 May 2002, OGS subscribed SEK52.0 million in cash at SEK39.1 per share in BioInvent International AB, as part of a research collaboration. At 30 June 2002, BioInvent International AB's share price was SEK28.5 per share. However, this investment, and the investment in NeoGenesis Pharmaceuticals Inc, is not held for resale and management do not consider that any permanent diminution in value existed at that date. (I can't translate.... anybody else? Is the value of their NeoG holding hidden in there, someplace?)